Several serologic markers of liver fibrosis have been developed in last years. Among them, Aspartate-to-Platelet Ratio Index (APRI) has demonstrated good correlation with liver biopsy in advanced stages of fibrosis and has been used in monitoring the fibrosis evolution in HIV/HCV co-infected individuals, in correlation with different cART regimens. Nevertheless, data on APRI score in patients treated with INSTI are still lacking. In the context of the SCOLTA project HIV/HCV co-infected patients who started raltegravir (RAL), the first-in class INSTI, have been prospectively followed-up for 24 months. Globally, 124 patients (71.0% males) started RAL with PI (n=95, 76.6%) or with NRTI (n= 29, 23.4%). At the end of follow-up 94 patients were observed: 73 in treatment with PI and 21 with NRTI. The difference between APRI values at 24 months and baseline was 0.0 (IQR -0.4-0.2) in PI group (+ 0.0%) and -0.2 (IQR -1.1-0.1) in NRTI group (-14.3%). Although our work considers a limited number of patients and a short follow-up, RAL use in HIV/HCV individuals has not been linked to worsening of APRI in any group of patients, suggesting that RAL can be safely used in HIV/HCV co-infected patients.
To cite this article
Aspartate-to-platelet ratio index evaluation in a cohort of HIV/HCV infected patients treated with raltegravir
Infectious Diseases & Tropical Medicine 2018; 4 (3): e490
Submission date: 04 Sep 2018
Revised on: 10 Sep 2018
Accepted on: 14 Sep 2018
Published online: 26 Sep 2018
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.